Apellis Pharmaceuticals’ (APLS) Buy Rating Reiterated at HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $92.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 115.71% from the company’s previous close.

APLS has been the topic of a number of other reports. Wedbush cut their price target on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group lifted their price target on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Oppenheimer upped their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $77.13.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS traded down $1.25 during mid-day trading on Wednesday, reaching $42.65. 1,791,482 shares of the company were exchanged, compared to its average volume of 1,575,431. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The stock has a market capitalization of $5.17 billion, a P/E ratio of -9.51 and a beta of 0.97. The company’s 50-day simple moving average is $54.74 and its 200-day simple moving average is $57.53. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. During the same period in the prior year, the company earned ($1.56) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 284.3% on a year-over-year basis. As a group, research analysts predict that Apellis Pharmaceuticals will post -1.27 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $77,799.96. Following the transaction, the insider now directly owns 92,453 shares in the company, valued at approximately $6,265,539.81. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $77,799.96. Following the completion of the transaction, the insider now owns 92,453 shares in the company, valued at approximately $6,265,539.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. In the last quarter, insiders sold 376,427 shares of company stock valued at $23,169,639. Insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of APLS. First Horizon Advisors Inc. increased its stake in Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after purchasing an additional 265 shares during the last quarter. Future Financial Wealth Managment LLC purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $29,000. Covestor Ltd boosted its position in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth approximately $89,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 29.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after buying an additional 687 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).